- ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
- ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
- ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
- ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
- ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
- ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
- ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
- ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
- ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
- ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
More ▼
Key statistics
On Friday, ReShape Lifesciences Inc (RSLS:NAQ) closed at 0.2062, 45.83% above the 52 week low of 0.1414 set on Feb 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.1988 |
---|---|
High | 0.21 |
Low | 0.1931 |
Bid | 0.2024 |
Offer | 0.2061 |
Previous close | 0.2257 |
Average volume | 1.45m |
---|---|
Shares outstanding | 23.46m |
Free float | 20.84m |
P/E (TTM) | -- |
Market cap | 4.84m USD |
EPS (TTM) | -2.30 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼